Network Meta-Analysis of 107 RCTs on Chinese Herbal Medicines for Endometriosis

A network meta-analysis of 107 randomized controlled trials evaluating the efficacy and safety of blood-invigorating Chinese herbal medicines combined with conventional therapy for endometriosis. The analysis was conducted by Weiru Liu and published on figshare in May 2026. It compares multiple interventions across primary outcomes including clinical efficacy, pain scores, hormone levels, and recurrence rates.

Use Cases

• Ranking the comparative efficacy of different Chinese herbal medicine regimens based on SUCRA values reported in the analysis.
• Evaluating the impact of combined therapies on pain reduction based on visual analog scale (VAS) scores.
• Assessing the effect of interventions on hormonal regulation based on reported changes in E2, FSH, and LH levels.
• Comparing the safety profiles of different treatment combinations based on reported adverse event incidence.

Strengths

• Includes 107 randomized controlled trials, providing a substantial evidence base.
• Analyzes multiple primary outcomes including clinical efficacy, pain VAS, sex hormones, CA125, cyst diameter, recurrence, and adverse events.
• Uses a network meta-analysis framework with SUCRA ranking to compare multiple interventions directly and indirectly.

Limitations

• The dataset is a 144.2 KB PDF summary; the underlying trial-level data is not provided, limiting reproducibility and secondary analysis.
• Row count and column-level documentation are unknown, which may limit suitability assessment.
• Data may reflect publication or language bias inherent to the included databases (e.g., CNKI, WanFang).

Provenance

Source

Weiru Liu via figshare

Collection Method

Systematic review and network meta-analysis of RCTs from eight databases (CNKI, WanFang, VIP, SinoMed, PubMed, EMBASE, Cochrane Library, Web of Science).

Time Range

Trials searched from database inception to 16 June 2025.

Freshness

Last updated 2026-05-13 05:53:54